| Sep 3 |
Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
|
| Sep 2 |
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
|
| Aug 10 |
Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 10 |
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
|
| Aug 6 |
Corvus Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05
|
| Aug 6 |
Corvus Pharmaceuticals files for $200M mixed securities shelf
|
| Aug 6 |
Corvus: Q2 Earnings Snapshot
|
| Aug 6 |
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
|
| Aug 1 |
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
|
